GlassScriptPhysician profile
Sidney Ariel Schechet
NPI 1659714707
$22,661.15
in general payments reported to CMS, 2019-2025
18 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,901 · 2020: $8,224 · 2021: $4,041 · 2022: $5,443 · 2023: $2,564 · 2024: $339 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,400 · Food and Beverage: $503 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,400.00 |
| Food and Beverage | $503.32 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $9,987.49 | 2019-2024 | Iluvien, Yutiq |
| Biogen, INC. | $5,964.31 | 2020-2023 | |
| Allergan, INC. | $3,431.52 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $1,128.97 | 2019 | |
| Genentech USA, INC. | $532.90 | 2019-2025 | Vabysmo, Susvimo |
| Regeneron Healthcare Solutions, INC. | $398.61 | 2019-2025 | Eylea, Eylea Hd |
| Alcon Vision LLC | $292.45 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $219.82 | 2019-2021 | |
| Cardinal Health 110 LLC | $150.00 | 2024 | |
| Spark Therapeutics, INC. | $124.55 | 2019 | |
| Abbvie INC. | $114.60 | 2022-2025 | |
| Genentech, INC. | $96.92 | 2021 | |
| Bausch & Lomb Americas INC. | $78.59 | 2023-2024 | Xipere |
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Harrow Eye, LLC | $30.83 | 2025 | Iheezo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $21.59 | 2023 | |
| Sandoz INC. | $18.24 | 2024 | Cimerli |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Schechet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.